Brain Tumor Drugs Market is expected to record a CAGR of 9.2% during the 2023 to 2033

The Brain Tumor Drugs Market is likely to grow from US$ 2.65 billion in 2023 to US$ 6.30 billion in 2033, at a CAGR 9.2%.

Growing Use of Targeted Medicines is Putting a Damper on the Brain Tumor Medications Industry

The goal of targeted cancer therapy is to eliminate cancerous cells while leaving healthy cells alone. Because it concentrates on changes in the cell that are specific to cancer, this therapy may be more effective than traditional chemotherapy and radiotherapy. Everolimus, for example, is a targeted drug that inhibits the growth and spread of cancer cells.

A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16725

Bevacizumab, on the other hand, stops cancer cell renewal, unlike chemical medicines, which cannot. The growing popularity of targeted therapy is projected to have an influence on sales of traditional chemical brain tumour drugs, limiting market growth over the forecast period. Businesses in the brain tumour industry are focusing on the use of nanotechnology for novel treatment.

Nanoparticles are used to deliver drugs directly to cancer cells or tumours in combination. This approach has also resulted in decreased medication dosage, extended shelf life, and decreased toxicity. A few nano medicines have been shown to be effective in crossing the blood-brain barrier, which has been a significant barrier in the treatment of brain cancer.

A brain tumour is an abnormal mass of tissue in which brain cells multiply and develop uncontrollably and rapidly. Primary brain tumours and metastatic brain tumours are the two forms of brain cancer. Primary brain tumours develop from the brain’s tissues or surrounding tissues.

Pharmaceutical companies have improved supply chain management, which has resulted in greater R&D and investment in quality control and manufacturing.

Key Takeaways

• The brain tumor drugs market is expected to record a CAGR of 9.2% during the forecast period 2023 to 2033.
• The primary drivers of the market are an increase in brain cancer prevalence, the presence of promising pipeline candidates, and an increased need for precision and customized treatment to drive market expansion.
• North America dominated the brain tumor drugs market.

Get a Discount on the Report@ https://www.futuremarketinsights.com/request-discount/rep-gb-16725

Prominent Participants in the Market

• AstraZeneca plc
• Johnson & Johnson Inc
• Merck & Co
• Pfizer Inc
• F. Hoffmann-La Roche Ltd
• Y-mAbs Therapeutics, Inc
• Shimadzu Corporation
• Bristol-Myers Squibb
• Bayer AG
• Dr. Reddy’s Laboratories Ltd
• Among others

Key Development in the Brain Tumor Drugs Market

• MindMed and Nextage Therapeutics inked a Memorandum of Understanding (MOU) in April 2021 to optimise the administration of selected psychedelic drug candidates using Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology.
• In March 2021, Roche and GenMark Diagnostics inked a complete merger agreement under which Roche will acquire GenMark in an all-cash transaction for US$ 24.05 per share.
• F. Hoffmann-La Roche Ltd. announced an agreement to buy Good Therapeutics in September 2022. With this acquisition, the company gains access to Good Therapeutic’s platform technology, which is applicable to a variety of industries like cancer, autoimmune diseases, metabolic disease, and pain management.
• Novartis AG got FDA approval for Tafinlar + Mekinist in June 2022 for the treatment of paediatric and adult patients with solid tumours carrying the BRAF V600E mutation. BRAF mutations cause tumour growth in approximately 20 different types of tumours, including brain, thyroid, and others.
• Pfizer Inc. acquires Trillium Therapeutics, a clinical-stage immuno-oncology firm focusing on developing innovative cancer therapies, in November 2021.

Visit for Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16725

Key Segment

By Therapy:

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Indication:

• Pituitary
• Meningioma
• Glioma
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail & Online Pharmacy

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs